FI884013A0 - CONJUGATED AV CYTOKINER MED IMMUNOGLOBULINER. - Google Patents
CONJUGATED AV CYTOKINER MED IMMUNOGLOBULINER.Info
- Publication number
- FI884013A0 FI884013A0 FI884013A FI884013A FI884013A0 FI 884013 A0 FI884013 A0 FI 884013A0 FI 884013 A FI884013 A FI 884013A FI 884013 A FI884013 A FI 884013A FI 884013 A0 FI884013 A0 FI 884013A0
- Authority
- FI
- Finland
- Prior art keywords
- immunoglobuliner
- cytokiner
- med
- conjugated
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The conjugates consist of a cytokine, for example interferon alpha, and human immunoglobulin, if required linked via an organic bridge and are used in pharmaceutical preparations for the treatment of viral infections and tumours. Compared with the free cytokine, the conjugates have a longer residence time in the plasma and tissue and thus improve the therapeutic effect.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH335787 | 1987-09-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
FI884013A0 true FI884013A0 (en) | 1988-08-31 |
FI884013A FI884013A (en) | 1989-03-03 |
Family
ID=4254228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI884013A FI884013A (en) | 1987-09-02 | 1988-08-31 | CONJUGATED AV CYTOKINER MED IMMUNOGLOBULINER. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0305967B1 (en) |
JP (1) | JPS6490200A (en) |
KR (1) | KR890005137A (en) |
AT (1) | ATE88900T1 (en) |
AU (1) | AU627694B2 (en) |
DE (1) | DE3880766D1 (en) |
DK (1) | DK486588A (en) |
ES (1) | ES2054753T3 (en) |
FI (1) | FI884013A (en) |
IL (1) | IL87621A0 (en) |
NO (1) | NO883896L (en) |
NZ (1) | NZ226005A (en) |
PH (1) | PH26813A (en) |
PT (1) | PT88385B (en) |
ZA (1) | ZA886471B (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3818055A1 (en) * | 1988-05-27 | 1989-11-30 | Biotest Pharma Gmbh | COMBINATION OF HUMAN IMMUNOGLOBULINS AND INTERLEUKIN-2 FOR THE TREATMENT OF INFECTION DISEASES |
GB8820378D0 (en) * | 1988-08-26 | 1988-09-28 | Offord R E | Chemical compounds |
GB8820377D0 (en) * | 1988-08-26 | 1988-09-28 | Offord R E | Chemical compounds |
KR900005995A (en) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
DE3839332A1 (en) * | 1988-11-22 | 1990-05-23 | Bayer Ag | METHOD FOR PRODUCING SUBSTITUTED 2-CHLORINE PYRIDINES |
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5478804A (en) * | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
DE69204990T2 (en) * | 1991-01-03 | 1996-05-15 | Salk Inst For Biological Studi | MITOTOXIN FOR TREATMENT OF VESSEL DAMAGE. |
IE920366A1 (en) * | 1991-02-04 | 1992-08-12 | Univ Saskatchewan | Vp6 encapsulated drug delivery |
DE69213030D1 (en) * | 1991-02-04 | 1996-09-26 | Univ Saskatchewan | Drug delivery from VP6 capsules |
JP3105629B2 (en) * | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | Cell activity regulating conjugates of members of specific binding pairs |
EP0533006A1 (en) * | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
US7754211B2 (en) | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
CA2218737C (en) * | 1996-04-10 | 2003-12-16 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
IT1289608B1 (en) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL |
EP1037927B1 (en) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
MXPA02001417A (en) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Multiple cytokine-antibody complexes. |
ES2269366T3 (en) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
CZ304942B6 (en) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Medicament for increasing specific elimination of tumor cell population and pharmaceutical composition containing phosphate-FITC conjugate or phosphate-dinitrophenyl |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
CN1330664C (en) | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | Expression technology for proteins containing hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
CN100503639C (en) | 2001-05-03 | 2009-06-24 | 默克专利有限公司 | Recombinant tumor specific antibody and use thereof |
EP1414471B1 (en) | 2001-07-17 | 2012-06-13 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
MXPA04005266A (en) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Immunocytokines with modulated selectivity. |
US7169904B2 (en) | 2002-12-17 | 2007-01-30 | Emd Lexigen Research Center Corp. | Immunocytokine sequences and uses thereof |
WO2005063820A2 (en) | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
WO2005070967A2 (en) | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
ES2384055T3 (en) | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variants of interleukin-12p40 with improved stability |
PT2270050E (en) | 2005-12-30 | 2013-09-12 | Merck Patent Gmbh | Anti-cd19 antibodies with reduced immunogenicity |
CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
JP5879713B2 (en) * | 2010-12-09 | 2016-03-08 | ソニー株式会社 | Image processing apparatus, image processing method, and program |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
EP2986312B1 (en) | 2013-04-19 | 2021-12-15 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1564666A (en) * | 1978-05-31 | 1980-04-10 | Ng Mun Hon | Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof |
-
1988
- 1988-08-30 EP EP88114130A patent/EP0305967B1/en not_active Expired - Lifetime
- 1988-08-30 AT AT88114130T patent/ATE88900T1/en not_active IP Right Cessation
- 1988-08-30 PH PH37474A patent/PH26813A/en unknown
- 1988-08-30 ES ES88114130T patent/ES2054753T3/en not_active Expired - Lifetime
- 1988-08-30 DE DE8888114130T patent/DE3880766D1/en not_active Expired - Fee Related
- 1988-08-31 FI FI884013A patent/FI884013A/en not_active IP Right Cessation
- 1988-08-31 NZ NZ226005A patent/NZ226005A/en unknown
- 1988-08-31 PT PT88385A patent/PT88385B/en not_active IP Right Cessation
- 1988-08-31 IL IL87621A patent/IL87621A0/en unknown
- 1988-08-31 ZA ZA886471A patent/ZA886471B/en unknown
- 1988-09-01 DK DK486588A patent/DK486588A/en not_active Application Discontinuation
- 1988-09-01 AU AU21725/88A patent/AU627694B2/en not_active Ceased
- 1988-09-01 KR KR1019880011274A patent/KR890005137A/en not_active Application Discontinuation
- 1988-09-01 NO NO88883896A patent/NO883896L/en unknown
- 1988-09-01 JP JP63216441A patent/JPS6490200A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NO883896D0 (en) | 1988-09-01 |
NO883896L (en) | 1989-03-03 |
DK486588D0 (en) | 1988-09-01 |
AU627694B2 (en) | 1992-09-03 |
EP0305967A2 (en) | 1989-03-08 |
FI884013A (en) | 1989-03-03 |
EP0305967A3 (en) | 1990-01-31 |
ATE88900T1 (en) | 1993-05-15 |
DK486588A (en) | 1989-03-03 |
ES2054753T3 (en) | 1994-08-16 |
PT88385A (en) | 1989-07-31 |
AU2172588A (en) | 1989-03-23 |
JPS6490200A (en) | 1989-04-06 |
EP0305967B1 (en) | 1993-05-05 |
KR890005137A (en) | 1989-05-13 |
ZA886471B (en) | 1989-04-26 |
PT88385B (en) | 1992-10-30 |
IL87621A0 (en) | 1989-01-31 |
NZ226005A (en) | 1990-10-26 |
PH26813A (en) | 1992-11-05 |
DE3880766D1 (en) | 1993-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI884013A (en) | CONJUGATED AV CYTOKINER MED IMMUNOGLOBULINER. | |
DE3776946D1 (en) | NASAL ADMINISTRATION OF MEDICINAL PRODUCTS. | |
GEP19981482B (en) | Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B | |
NO943901L (en) | Methods and Preparations for the Treatment of Diseases with Interferon While Reducing Side Effects | |
DE68929551D1 (en) | Human DNase | |
FI862011A0 (en) | THERAPEUTIC NUCLEOSIDER. | |
AU5646886A (en) | Therapeutical application of phosphonylmethoxyalkyl adenines | |
DE68914644D1 (en) | REDUCING SIDE EFFECTS IN CANCER THERAPY. | |
DK602988A (en) | NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL EFFECT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS | |
ATE197670T1 (en) | PARENTERAL BUSULFAN FOR THE TREATMENT OF MALIGNANT DISEASES | |
NO931413D0 (en) | METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES | |
DE68912155D1 (en) | Combination antiviral. | |
DK68388D0 (en) | APPLICATION OF OXOCHINAZOLINE DERIVATIVES FOR THE PREPARATION OF MEDICINAL PRODUCTS TO TREAT HYPERURIC AEMIA | |
ES2037807T3 (en) | MEDICINES CONTAINING IN INTERFERON COMBINATION AND 1-DEOXY-PIPERIDINES, PROCEDURE FOR THEIR MANUFACTURE AND APPLICATION. | |
EA199800770A1 (en) | DRUGS FOR THERAPEUTIC TREATMENT OF VIRAL HEPATITIS | |
NO953003L (en) | Use of ifenprodil and its diastereoisomers for the preparation of medical preparations | |
DK0427633T3 (en) | Use of a polypeptide with gamma interferon activity for the preparation of pharmaceutical preparations intended for the treatment of primitive pleural cancer | |
ES2038578T1 (en) | USE OF HUMAN G IMMUNOGLOBULINS, OR OF THESE FC FRAGMENTS, AS A PREPARATORY MEDICINE FOR THE ADMINISTRATION OF MONOCLONAL ANTIBODIES TO MEN. | |
NO900121L (en) | PROBURSIN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed | ||
MM | Patent lapsed |
Owner name: CIBA-GEIGY AG |